Last reviewed · How we verify
Microtransplantation
At a glance
| Generic name | Microtransplantation |
|---|---|
| Sponsor | Ahmed Galal, MD |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies (Phase 1)
- Efficacy and Safety of Microtransplantation for Advanced and Relapsed Solid Tumors (Phase 1)
- Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia (Phase 1)
- A Clinical Study to Evaluate the Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk Myelodysplastic Syndromes (Phase 2)
- Efficacy and Safety of Radiotherapy or Chemotherapy Combined With Microtransplantation in the Treatment of Advanced and Relapsed Solid Tumors (Phase 1)
- HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia (Phase 3)
- NCT01674985 (Phase 1)
- Phase 2 Study of Venetoclax-containing Therapy in Combination With HLA-mismatched Mobilized Peripheral Blood Mononuclear Cell Infusion for Intermediate-risk and Higher Myelodysplastic Syndromes (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Microtransplantation CI brief — competitive landscape report
- Microtransplantation updates RSS · CI watch RSS
- Ahmed Galal, MD portfolio CI